{"log_id": 6907475713772439561, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 7e-06, "average": 0.998369, "min": 0.986778}, "location": {"width": 763, "top": 221, "height": 32, "left": 213}, "words": "的短期治疗研究,患者服用盐酸托莫西汀或安慰剂。盐酸托莫西汀在早晨单次服用,并根"}, {"probability": {"variance": 0.010486, "average": 0.974301, "min": 0.409783}, "location": {"width": 761, "top": 259, "height": 32, "left": 212}, "words": "据临床效果以体重为基础进行剂调整,最大剂量达1.5mg/kg日。盐酸托莫西汀平均最终"}, {"probability": {"variance": 0.00231, "average": 0.984815, "min": 0.706026}, "location": {"width": 761, "top": 298, "height": 30, "left": 213}, "words": "剂量约为1.3mg/kg日。根据 ADHDRS评分,盐酸托莫西汀组ADHD症状的改善优于安慰"}, {"probability": {"variance": 4.2e-05, "average": 0.996582, "min": 0.965588}, "location": {"width": 731, "top": 335, "height": 31, "left": 213}, "words": "剂组,并具有统计学意义。该研究显示,每日早晨服用一次盐酸托莫西汀胶囊是有效的"}, {"probability": {"variance": 0.006614, "average": 0.974969, "min": 0.582545}, "location": {"width": 724, "top": 373, "height": 32, "left": 250}, "words": "在2项同样对7至13岁儿童(研究3,N=147;研究4,N=144)进行的9周短期、随"}, {"probability": {"variance": 0.00717, "average": 0.978686, "min": 0.551203}, "location": {"width": 753, "top": 414, "height": 27, "left": 212}, "words": "机、双盲、安慰剂对照研究中,将盐酸托莫西汀胶囊和哌甲酯与安慰剂进行比较。盐酸打"}, {"probability": {"variance": 1.9e-05, "average": 0.997353, "min": 0.98187}, "location": {"width": 740, "top": 451, "height": 28, "left": 213}, "words": "莫西汀胶囊分早晨和傍晚(放学后)两次服用,并根据临床效果以体重为基础调整剂量"}, {"probability": {"variance": 0.00409, "average": 0.982273, "min": 0.599}, "location": {"width": 756, "top": 491, "height": 26, "left": 212}, "words": "盐酸托莫西汀胶囊最大推荐剂量为2.0mg/kg/日,在两项研究中,盐酸托莫西汀的平均最终"}, {"probability": {"variance": 0.004718, "average": 0.977979, "min": 0.575843}, "location": {"width": 760, "top": 528, "height": 26, "left": 212}, "words": "剂量都是约1.6mg/kg/日。根据 ADHDRS评分结果,盐酸托莫西汀组ADHD症状的改善均"}, {"probability": {"variance": 0.002275, "average": 0.985948, "min": 0.807549}, "location": {"width": 291, "top": 567, "height": 24, "left": 212}, "words": "优于安慰剂组,并具有统计学意义"}, {"probability": {"variance": 0.001443, "average": 0.988342, "min": 0.826257}, "location": {"width": 721, "top": 605, "height": 25, "left": 250}, "words": "按照性别和年龄(<12和12至17)亚组进行分析,未发现任何疗效差异。除高加索"}, {"probability": {"variance": 5.9e-05, "average": 0.995734, "min": 0.965078}, "location": {"width": 478, "top": 642, "height": 25, "left": 213}, "words": "人,在这些亚组中没有足够的暴露量进行种族差异的考察"}, {"probability": {"variance": 0.001088, "average": 0.988026, "min": 0.816785}, "location": {"width": 722, "top": 681, "height": 25, "left": 250}, "words": "维持研究一一项在儿童和青少年(6-15岁)门诊患者中进行的研究确定了本品维持治"}, {"probability": {"variance": 0.000768, "average": 0.986972, "min": 0.836845}, "location": {"width": 762, "top": 718, "height": 26, "left": 211}, "words": "疗ADHD的疗效。在本品(1.2-1.8mg/kg天)最初10周开放治疗阶段期间持续应答4周的"}, {"probability": {"variance": 0.000318, "average": 0.992203, "min": 0.91873}, "location": {"width": 762, "top": 757, "height": 26, "left": 210}, "words": "符合DSM- IV ADHD标准的患者随机入组,在双盲阶段继续给予当前剂量的托莫西汀"}, {"probability": {"variance": 0.000739, "average": 0.988673, "min": 0.87591}, "location": {"width": 740, "top": 794, "height": 25, "left": 230}, "words": "N=292)或安慰剂(N=124),以观察复发情况。开放阶段的应答定议为CGI-ADHD-S评"}, {"probability": {"variance": 0.000467, "average": 0.992724, "min": 0.872468}, "location": {"width": 754, "top": 831, "height": 27, "left": 216}, "words": "分≤2且受试者 DHDRS- .iv-parent量表总分相对于基线至少降低25%。在双盲治疗第一阶"}, {"probability": {"variance": 0.000368, "average": 0.993981, "min": 0.881801}, "location": {"width": 762, "top": 869, "height": 28, "left": 212}, "words": "段期间托莫西汀组持续应答约8个月的患者,继续服用当前剂量(N=81)或安慰剂"}, {"probability": {"variance": 0.01521, "average": 0.964427, "min": 0.41307}, "location": {"width": 741, "top": 908, "height": 25, "left": 231}, "words": "N=82)以观察复发情况。双阶段的复发定义为CGADHD-S评分相对于开放阶段终"}, {"probability": {"variance": 0.000849, "average": 0.990225, "min": 0.840288}, "location": {"width": 758, "top": 945, "height": 26, "left": 214}, "words": "点至少增加2分以及受试者 ADHDRS-V- Parent总分回复到两次连续访视评分的90%以"}, {"probability": {"variance": 0.008598, "average": 0.979066, "min": 0.440893}, "location": {"width": 715, "top": 981, "height": 32, "left": 211}, "words": "上。两个双盲阶段中,患者继续服用托莫西汀治疗至出现复发的时间显著长慰剂"}, {"probability": {"variance": 1e-06, "average": 0.998251, "min": 0.997113}, "location": {"width": 42, "top": 1025, "height": 25, "left": 212}, "words": "成人"}, {"probability": {"variance": 0.000791, "average": 0.962201, "min": 0.932001}, "location": {"width": 121, "top": 1029, "height": 34, "left": 844}, "words": "来贸易"}, {"probability": {"variance": 0.021949, "average": 0.922058, "min": 0.507524}, "location": {"width": 732, "top": 1058, "height": 39, "left": 247}, "words": "2项对符合DSMⅣV中ADHD诊断标准的18岁及以上成人进行的睡机双、共慰"}, {"probability": {"variance": 4e-05, "average": 0.995171, "min": 0.97403}, "location": {"width": 487, "top": 1097, "height": 29, "left": 213}, "words": "对照临床研究,确定了盐酸托莫西汀对成人ADHD的疗效"}, {"probability": {"variance": 0.009778, "average": 0.957595, "min": 0.529405}, "location": {"width": 719, "top": 1129, "height": 31, "left": 249}, "words": "研究者使用有30个条目的康纳斯成人多动症评定量表( CAARS)评估ADD的症状"}, {"probability": {"variance": 0.001392, "average": 0.986652, "min": 0.812547}, "location": {"width": 760, "top": 1171, "height": 28, "left": 213}, "words": "和体征。主要疗效指标是18项ADHD症状总分 CAARS中注意缺陷和多动/冲动分量表"}, {"probability": {"variance": 8.5e-05, "average": 0.996088, "min": 0.956061}, "location": {"width": 498, "top": 1209, "height": 27, "left": 212}, "words": "之和)在治疗前后的平均变化,使用的分析方法是意向治疗"}, {"probability": {"variance": 9e-06, "average": 0.995379, "min": 0.992357}, "location": {"width": 39, "top": 1209, "height": 21, "left": 855}, "words": "分析"}, {"probability": {"variance": 0.007088, "average": 0.979595, "min": 0.497619}, "location": {"width": 723, "top": 1245, "height": 27, "left": 250}, "words": "在2项同样的10周随机、双盲、安慰剂对照短期治疗研究中(研究5,N=280:研究"}, {"probability": {"variance": 0.006383, "average": 0.976137, "min": 0.550303}, "location": {"width": 728, "top": 1282, "height": 29, "left": 244}, "words": "N=256),患者服用盐酸托莫西汀或安慰剂。盐酸托莫西汀胶囊分早晨和傍晚两次服"}, {"probability": {"variance": 0.004385, "average": 0.983995, "min": 0.575424}, "location": {"width": 760, "top": 1320, "height": 28, "left": 213}, "words": "用,并根据临床效果,在60至120mg日的范围内调整剂量。在两项研究中,盐酸托莫西"}, {"probability": {"variance": 0.001708, "average": 0.987735, "min": 0.754268}, "location": {"width": 763, "top": 1357, "height": 31, "left": 210}, "words": "汀的平均最终剂量都约为95mg日。这两项研究表明,根据 CAARS评分结果,盐酸托莫"}, {"probability": {"variance": 0.007346, "average": 0.976813, "min": 0.541502}, "location": {"width": 527, "top": 1396, "height": 27, "left": 213}, "words": "西汀组ADHD症状的改善都优于安慰剂组,并具有统计学意义"}, {"probability": {"variance": 1e-06, "average": 0.999138, "min": 0.997967}, "location": {"width": 114, "top": 1368, "height": 61, "left": 974}, "words": "州医药"}, {"probability": {"variance": 0.000231, "average": 0.987508, "min": 0.96611}, "location": {"width": 185, "top": 1396, "height": 64, "left": 893}, "words": "限公司"}, {"probability": {"variance": 0.007059, "average": 0.966244, "min": 0.637476}, "location": {"width": 722, "top": 1433, "height": 26, "left": 250}, "words": "按照性别和年龄(<42和≥42,亚组进行分析,未发现任何疗效差异。除高加素人在"}, {"probability": {"variance": 2.2e-05, "average": 0.997565, "min": 0.977983}, "location": {"width": 424, "top": 1471, "height": 25, "left": 212}, "words": "这些亚组中没有足够的暴露量进行种族差异的考察"}, {"probability": {"variance": 0.058003, "average": 0.702497, "min": 0.429996}, "location": {"width": 209, "top": 1541, "height": 48, "left": 855}, "words": "S惠贸易三"}, {"probability": {"variance": 0.069682, "average": 0.819649, "min": 0.366683}, "location": {"width": 173, "top": 1560, "height": 78, "left": 864}, "words": "限公司"}, {"probability": {"variance": 0.059533, "average": 0.822275, "min": 0.376635}, "location": {"width": 139, "top": 1603, "height": 39, "left": 1017}, "words": "仅供存档"}], "language": 3}